NFBK Stock UPDATES Northfield Bancorp (NFBK) 12.78 08/02/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Northfield Bancorp (NFBK) 12.78 $NFBK

12.6% Return Seen to Date on SmarTrend Northfield Bancorp Call (NFBK)
Comtex SmarTrend(R) - Thu Jul 31, 9:25AM CDT
SmarTrend identified an Uptrend for Northfield Bancorp (NASDAQ:NFBK) on December 18th, 2012 at $11.46. In approximately 20 months, Northfield Bancorp has returned 12.61% as of today's recent price of $12.90.

Northfield Bancorp, Inc. Announces Second Quarter 2014 Results
GlobeNewswire - Wed Jul 23, 7:10PM CDT
NOTABLE ITEMS INCLUDE:

Northfield Bancorp Has Returned 11.7% Since SmarTrend Recommendation (NFBK)
Comtex SmarTrend(R) - Wed Jul 23, 5:08PM CDT
SmarTrend identified an Uptrend for Northfield Bancorp (NASDAQ:NFBK) on December 18th, 2012 at $11.46. In approximately 19 months, Northfield Bancorp has returned 11.65% as of today's recent price of $12.79.

Northfield Bancorp Up 11.4% Since SmarTrend Uptrend Call (NFBK)
Comtex SmarTrend(R) - Wed Jul 16, 9:28AM CDT
SmarTrend identified an Uptrend for Northfield Bancorp (NASDAQ:NFBK) on December 18th, 2012 at $11.46. In approximately 19 months, Northfield Bancorp has returned 11.39% as of today's recent price of $12.76.

Uptrend Call Working As Northfield Bancorp Stock Rises 15.0% (NFBK)
Comtex SmarTrend(R) - Tue Jul 01, 9:40AM CDT
SmarTrend identified an Uptrend for Northfield Bancorp (NASDAQ:NFBK) on December 18th, 2012 at $11.46. In approximately 19 months, Northfield Bancorp has returned 14.97% as of today's recent price of $13.17.

Shares of NFBK Up 17.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 09, 9:55AM CDT
SmarTrend identified an Uptrend for Northfield Bancorp (NASDAQ:NFBK) on December 18th, 2012 at $11.46. In approximately 18 months, Northfield Bancorp has returned 17.68% as of today's recent price of $13.48.

Should Northfield Bancorp (NFBK) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 21, 7:50AM CDT
Northfield Bancorp is well positioned for a solid gain, but has been overlooked by investors lately. This Banking stock has actually seen estimates rise over the past month for the current fiscal year by about 22.6%. But that is not yet reflected in its price, as the stock gained only 1.9% over the same time frame.

Northfield Bancorp, Inc. Adopts Second Repurchase Program; First Program Nearly Complete
GlobeNewswire - Fri Mar 07, 4:06PM CST
NORTHFIELD BANCORP, INC. (Nasdaq:NFBK), the holding company for Northfield Bank, announced that its initial repurchase program is nearly complete, having repurchased 2,198,002 shares of its common stock of the 2,886,312 shares approved in that initial program. The Company's Board of Directors adopted a second stock repurchase program to begin at the conclusion of the initial program. In the second repurchase program, the Company may repurchase up to 2,751,460 shares of its common stock, or approximately 5% of the shares outstanding at the end of the initial program. The timing of the repurchases will depend on certain factors, including but not limited to, market conditions and prices, the Company's liquidity and capital requirements, and alternative uses of capital. Any repurchased shares will be held as treasury stock and will be available for general corporate purposes. The Company anticipates conducting such repurchases in accordance with a SEC Rule 10b5-1 trading plan.

Upgrade Alert for Northfield Bancorp (NFBK)
Comtex SmarTrend(R) - Wed Feb 05, 7:03AM CST
Northfield Bancorp (NASDAQ:NFBK) was upgraded from Market Perform to Outperform at Keefe Bruyette today. The stock closed yesterday at $12.43 on volume of 189,000 shares, above average daily volume of 144,000. In the past 52 weeks, Northfield Bancorp share prices have been bracketed by a low of $11.18 and a high of $13.43 and closed yesterday at $12.43, 11% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has remained constant.

Northfield Bancorp, Inc. Announces Fourth Quarter and Year End 2013 Results
GlobeNewswire - Wed Jan 29, 6:32PM CST
NOTABLE ITEMS INCLUDE:



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 3

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 1

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Updated Category News Views 2

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

Continue Reading
Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 3

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading

Top 5 Most Recently Viewed Articles

Prologis Earnings Report: Investors' Key Insights and Analysis

Updated Category News Views 138

Understanding Prologis's Upcoming Quarterly Earnings Prologis (NYSE: PLD) is set to release its latest quarterly earnings report, and investors are eagerly awaiting the insights it will provide. As the company approaches its earnings announcement, analysts project an earnings per share (EPS) of $1.02, which serves as a benchmark for performance expectations. Investor...

Continue Reading
How Changing U.S. Jobs Report Affects Market Dynamics

Updated Category News Views 171

The recent U. S. employment report sent shockwaves through financial markets, reshaping how traders and investors eyed their portfolios. Stronger-than-expected job creation—with figures soaring over 100,000—meant one thing: the narrative on interest rates was about to change. Gone were the days of comfortably betting on rate cuts; now, everyone’s scrambling to...

Continue Reading
Suno Boosts Innovation for Creators by Acquiring WavTool

Updated Category News Views 157

Suno Boosts Innovation for Creators by Acquiring WavTool Suno has recently made a significant move in the music industry with their acquisition of WavTool. This strategic decision aims to enhance their offerings for songwriters and producers, enabling them to create music that resonates with a broader audience. By integrating WavTool's advanced capabilities into their...

Continue Reading
Leqembi's New IV Treatment Approval: A Milestone for Alzheimer’s Care

Updated Category News Views 274

Leqembi Approved for IV Maintenance Treatment BioArctic AB, a notable player in the biopharmaceutical sector, has made significant headlines with the approval of Leqembi (lecanemab) for intravenous (IV) maintenance treatment for Alzheimer’s disease in the United Kingdom. This groundbreaking decision was announced following rigorous evaluations by the Medicines and...

Continue Reading
Investors of ATYR, MLTX, BAX, and JHX Have Legal Options

Updated Category News Views 145

Overview of Class Action Lawsuits for ATYR, MLTX, BAX, JHX Attention investors! If you’ve invested in aTyr Pharma Inc. (NASDAQ: ATYR), MoonLake Immunotherapeutics (NASDAQ: MLTX), Baxter International, Inc. (NYSE: BAX), or James Hardie Industries plc (NYSE: JHX), it’s important to be aware of significant class action lawsuits affecting your investments. These companies...

Continue Reading